Celgene Corporation

Celgene Corporation

Celgene Corporation was a global biopharmaceutical company that focused on the discovery, development, and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The company was headquartered in Summit, New Jersey, United States.

History

Celgene was founded in 1986 as a unit of the Celanese Corporation, a chemical company. It became an independent company in 1987. Over the years, Celgene grew through strategic acquisitions and the development of a robust pipeline of drugs.

In 2019, Celgene was acquired by Bristol-Myers Squibb in a deal valued at approximately $74 billion, one of the largest pharmaceutical mergers in history.

Products

Celgene's portfolio included several key products:

• Revlimid (lenalidomide): A drug used to treat multiple myeloma and myelodysplastic syndromes.
• Pomalyst (pomalidomide): Used for the treatment of multiple myeloma.
• Otezla (apremilast): A treatment for psoriatic arthritis and plaque psoriasis.
• Thalomid (thalidomide): Used for multiple myeloma and erythema nodosum leprosum.

Research and Development

Celgene was known for its strong focus on research and development, investing a significant portion of its revenue back into R&D. The company had a number of promising compounds in its pipeline, targeting various forms of cancer and inflammatory diseases.

Acquisitions

Celgene expanded its capabilities and product offerings through several strategic acquisitions, including:

• Abraxis BioScience: Acquired in 2010, bringing the drug Abraxane (paclitaxel protein-bound) into Celgene's portfolio.
• Receptos: Acquired in 2015, adding ozanimod, a drug for multiple sclerosis and ulcerative colitis, to its pipeline.

Corporate Social Responsibility

Celgene was committed to corporate social responsibility, focusing on improving patient access to medicines, supporting communities, and promoting environmental sustainability.

Acquisition by Bristol-Myers Squibb

In January 2019, Bristol-Myers Squibb announced its intention to acquire Celgene. The acquisition was completed in November 2019, creating a leading biopharmaceutical company with a strong portfolio of oncology, immunology, and cardiovascular products.

Legacy

Celgene's legacy continues through its contributions to the treatment of cancer and inflammatory diseases, as well as its impact on the biopharmaceutical industry through its innovative research and development efforts.

References

• Bristol-Myers Squibb Official Website
• Celgene Corporation 2018 Annual Report

External Links

• Celgene at Bristol-Myers Squibb